Department of Pharmacy, University of Naples "Federico II" , Via D. Montesano 49, I-80131 Naples, Italy.
J Med Chem. 2014 Oct 23;57(20):8477-95. doi: 10.1021/jm501273r. Epub 2014 Oct 9.
Nuclear and G-protein coupled receptors are considered major targets for drug discovery. FXR and GP-BAR1, two bile acid-activated receptors, have gained increasing consideration as druggable receptors. Because endogenous bile acids often target both receptor families, the development of selective ligands has been proven difficult, exposing patients to side effects linked to an unwanted activation of one of the two receptors. In the present study, we describe a novel library of semisynthetic bile acid derivatives obtained by modifications on the cholane scaffold. The pharmacological characterization of this library led to the discovery of 7α-hydroxy-5β-cholan-24-sulfate (7), 6β-ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (EUDCOH, 26), and 6α-ethyl-3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol (NorECDCOH, 30) as novel ligands for FXR and GP-BAR1 that might hold utility in the treatment of FXR and GP-BAR1 mediated disorders.
核受体和 G 蛋白偶联受体被认为是药物发现的主要靶点。法尼醇 X 受体(FXR)和 G 蛋白偶联受体 1(GP-BAR1),两种胆酸激活受体,作为可成药的受体越来越受到关注。由于内源性胆酸通常靶向这两个受体家族,因此开发选择性配体已被证明具有挑战性,使患者面临与两个受体之一的非预期激活相关的副作用。在本研究中,我们描述了一种新型半合成胆酸衍生物文库,该文库通过对胆烷骨架进行修饰获得。对该文库的药理学特征分析导致发现了 7α-羟基-5β-胆烷-24-磺酸(7)、6β-乙基-3α、7β-二羟基-5β-胆烷-24-醇(EUDCOH,26)和 6α-乙基-3α、7α-二羟基-24-降-5β-胆烷-23-醇(NorECDCOH,30),它们是 FXR 和 GP-BAR1 的新型配体,可能在治疗 FXR 和 GP-BAR1 介导的疾病方面具有应用价值。